Promoting Cholesterol Screening
|ClinicalTrials.gov Identifier: NCT01930149|
Recruitment Status : Completed
First Posted : August 28, 2013
Last Update Posted : September 29, 2014
Cholesterol screening is an important prerequisite for cardiovascular disease (CVD) risk assessment. Cholesterol screening is recommended by the United States Preventive Services Task Force (USPSTF). Since reminder systems have been shown to modestly improve the rates of preventive services, including in safety net settings, we will implement patient-directed reminders to health center patients who meet our eligibility criteria.
The aim of this study is to determine if a mailed outreach message and facilitated ordering of screening lipid tests increases cholesterol screening test completion within 3 months among federally qualified community health center patients who are eligible for screening compared to usual care.
|Condition or disease||Intervention/treatment|
|Cardiovascular Diseases Lipid Testing Primary Prevention of Cardiovascular Disease||Behavioral: Mailed patient outreach intervention|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||480 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Reducing Disparities in Primary Prevention of Cardiovascular Disease: Promoting Cholesterol Screening|
|Study Start Date :||December 2013|
|Primary Completion Date :||March 2014|
|Study Completion Date :||June 2014|
Experimental: Mailed patient outreach intervention
Participants randomized to this arm will receive mailed letter from health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
Behavioral: Mailed patient outreach intervention
This study's intervention is a mailed outreach letter from the health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
No Intervention: Usual Care Control Group
Participants randomized to this arm will receive usual care.
- Completion of total cholesterol and HDL cholesterol test or full lipid panel [ Time Frame: within 3 months of outreach ]Primary outcome will be completion of total cholesterol and HDL cholesterol test or a full lipid panel recorded within GE Centricity electronic health record at the patient's clinical site.
- Statin prescription [ Time Frame: within 3 months of outreach ]Secondary outcome is prescription of a statin as assessed by automated electronic queries of electronic health record.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01930149
|United States, Arizona|
|North Country Health Care|
|Flagstaff, Arizona, United States, 86004|
|United States, Illinois|
|Near North Health Service Corporation|
|Chicago, Illinois, United States, 60610|
|Heartland Health Outreach|
|Chicago, Illinois, United States, 60645|
|Principal Investigator:||Stephen D Persell, MD, MPH||Northwestern University|